Emerging therapies targeting cardiovascular risk factors to prevent or delay the onset of heart failure

Olisaemeka Zikora Akunne, Ogochukwu Emilia Anulugwo
{"title":"Emerging therapies targeting cardiovascular risk factors to prevent or delay the onset of heart failure","authors":"Olisaemeka Zikora Akunne, Ogochukwu Emilia Anulugwo","doi":"10.25259/ajpps_2024_013","DOIUrl":null,"url":null,"abstract":"Cardiovascular disease (CVD) poses a significant global health concern, contributing to nearly 30% of global deaths. Its prevalence is on the rise, necessitating a deeper understanding of associated risk factors including hypertension, cardiac hypertrophy, and diabetes. Addressing these risk factors is crucial in preventing or slowing the onset of heart failure (HF), a complex chronic condition with high morbidity and mortality rates. This review aims to explore innovative strategies for preventing or delaying HF, focusing on cardiovascular risk (CV) factors. Specifically, it delves into the link between hypertension, cardiac hypertrophy, diabetes, and HF emphasizing the importance of identifying new therapeutic approaches. A comprehensive examination of existing literature, clinical trials, and experimental models forms the basis of this review providing insights into the interconnected nature of cardiovascular risk factors and the efficacy of combination therapies. Evidence from diverse sources supports the adoption of a multifaceted approach to HF prevention. The review underscores the complex associations between hypertension, cardiac hypertrophy, diabetes, and HF highlighting the need for innovative therapeutic interventions. Clinical trials demonstrate promising outcomes with synergistic therapies such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors showcasing improved efficacy over single-agent interventions. In conclusion, adopting a multifaceted approach to HF prevention considering the interplay of various risk factors. Such an approach holds the potential for substantial benefits including simultaneous targeting of multiple pathways, individualized care, enhanced patient motivation, and reduced healthcare costs. Further research should focus on optimizing combination therapies and identifying patient population that stands to gain the most from these interventions providing a pathway towards improved cardiovascular health globally.","PeriodicalId":376259,"journal":{"name":"American Journal of Pharmacotherapy and Pharmaceutical Sciences","volume":"98 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Pharmacotherapy and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/ajpps_2024_013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiovascular disease (CVD) poses a significant global health concern, contributing to nearly 30% of global deaths. Its prevalence is on the rise, necessitating a deeper understanding of associated risk factors including hypertension, cardiac hypertrophy, and diabetes. Addressing these risk factors is crucial in preventing or slowing the onset of heart failure (HF), a complex chronic condition with high morbidity and mortality rates. This review aims to explore innovative strategies for preventing or delaying HF, focusing on cardiovascular risk (CV) factors. Specifically, it delves into the link between hypertension, cardiac hypertrophy, diabetes, and HF emphasizing the importance of identifying new therapeutic approaches. A comprehensive examination of existing literature, clinical trials, and experimental models forms the basis of this review providing insights into the interconnected nature of cardiovascular risk factors and the efficacy of combination therapies. Evidence from diverse sources supports the adoption of a multifaceted approach to HF prevention. The review underscores the complex associations between hypertension, cardiac hypertrophy, diabetes, and HF highlighting the need for innovative therapeutic interventions. Clinical trials demonstrate promising outcomes with synergistic therapies such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors showcasing improved efficacy over single-agent interventions. In conclusion, adopting a multifaceted approach to HF prevention considering the interplay of various risk factors. Such an approach holds the potential for substantial benefits including simultaneous targeting of multiple pathways, individualized care, enhanced patient motivation, and reduced healthcare costs. Further research should focus on optimizing combination therapies and identifying patient population that stands to gain the most from these interventions providing a pathway towards improved cardiovascular health globally.
针对心血管风险因素的新疗法,预防或延缓心力衰竭的发生
心血管疾病(CVD)是全球关注的重大健康问题,占全球死亡人数的近 30%。其发病率呈上升趋势,因此有必要深入了解相关的风险因素,包括高血压、心脏肥大和糖尿病。心力衰竭是一种复杂的慢性疾病,发病率和死亡率都很高,解决这些风险因素对于预防或减缓心力衰竭的发生至关重要。本综述旨在探讨预防或延缓心力衰竭的创新策略,重点关注心血管风险(CV)因素。特别是,它深入探讨了高血压、心脏肥大、糖尿病和高血压之间的联系,强调了确定新治疗方法的重要性。本综述以现有文献、临床试验和实验模型为基础,全面考察了心血管风险因素的相互关联性以及综合疗法的疗效。来自不同来源的证据支持采用多方面的方法来预防高血压。综述强调了高血压、心肌肥厚、糖尿病和心房颤动之间的复杂关联,突出了创新治疗干预的必要性。临床试验表明,血管紧张素转换酶(ACE)抑制剂、β-受体阻滞剂和钠-葡萄糖共转运体-2(SGLT-2)抑制剂等协同疗法的疗效很好,比单一药物干预效果更好。总之,考虑到各种风险因素的相互作用,采用多方面的方法来预防高血压。这种方法有可能带来巨大的益处,包括同时针对多种途径、个性化护理、提高患者积极性和降低医疗成本。进一步的研究应侧重于优化综合疗法,并确定从这些干预措施中获益最多的患者人群,为改善全球心血管健康提供途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信